The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement

Gianluca Tornese, Dario Iafusco, Lorenzo Monasta, Chiara Agnoletto, Veronica Tisato, Alessandro Ventura, Giorgio Zauli, Paola Secchiero

Research output: Contribution to journalArticle

Abstract

Experimental evidence in animal models suggests that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, might play an important role in type 1 diabetes (T1D). We have performed a retrospective study by analyzing the sera of a cohort of pediatric subjects (age 18 years; n = 507) consisting of (1) patients diagnosed with T1D (n = 387), (2) healthy individuals (n = 98, considered as controls), and (3) healthy autoantibody-positive subjects (n = 22). Patients with T1D exhibited significantly decreased levels of circulating TRAIL with respect to the control healthy subjects, as well as to the healthy autoantibody-positive subjects. Within the T1D group, no differences in the levels of circulating TRAIL were observed between patients with or without other concomitant autoimmune pathologies. Of note, the levels of TRAIL were significantly lower in the T1D patients analyzed at onset, although reduction in TRAIL levels persisted also in patients analyzed after disease onset (>1 year from diagnosis). In particular, T1D patients who exhibited ketoacidosis at onset showed significantly lower levels of circulating TRAIL with respect to patients without ketoacidosis at onset. Moreover, the levels of TRAIL at diagnosis correlated inversely with the insulin requirement up to 21 months of follow-up. This is the first study demonstrating that the levels of circulating TRAIL are significantly decreased in T1D, with the lowest levels of TRAIL being observed in patients with ketoacidosis at the onset and with the highest insulin requirement.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalActa Diabetologica
Volume51
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

TNF-Related Apoptosis-Inducing Ligand
Ketosis
Type 1 Diabetes Mellitus
Insulin
Autoantibodies
Healthy Volunteers
Animal Models
Retrospective Studies
Pediatrics
Pathology

Keywords

  • Insulin requirement
  • Ketoacidosis
  • TRAIL
  • Type 1 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. / Tornese, Gianluca; Iafusco, Dario; Monasta, Lorenzo; Agnoletto, Chiara; Tisato, Veronica; Ventura, Alessandro; Zauli, Giorgio; Secchiero, Paola.

In: Acta Diabetologica, Vol. 51, No. 2, 2014, p. 239-246.

Research output: Contribution to journalArticle

Tornese, Gianluca ; Iafusco, Dario ; Monasta, Lorenzo ; Agnoletto, Chiara ; Tisato, Veronica ; Ventura, Alessandro ; Zauli, Giorgio ; Secchiero, Paola. / The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. In: Acta Diabetologica. 2014 ; Vol. 51, No. 2. pp. 239-246.
@article{c2407cbf1b754efe9ea6d51232bdc260,
title = "The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement",
abstract = "Experimental evidence in animal models suggests that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, might play an important role in type 1 diabetes (T1D). We have performed a retrospective study by analyzing the sera of a cohort of pediatric subjects (age 18 years; n = 507) consisting of (1) patients diagnosed with T1D (n = 387), (2) healthy individuals (n = 98, considered as controls), and (3) healthy autoantibody-positive subjects (n = 22). Patients with T1D exhibited significantly decreased levels of circulating TRAIL with respect to the control healthy subjects, as well as to the healthy autoantibody-positive subjects. Within the T1D group, no differences in the levels of circulating TRAIL were observed between patients with or without other concomitant autoimmune pathologies. Of note, the levels of TRAIL were significantly lower in the T1D patients analyzed at onset, although reduction in TRAIL levels persisted also in patients analyzed after disease onset (>1 year from diagnosis). In particular, T1D patients who exhibited ketoacidosis at onset showed significantly lower levels of circulating TRAIL with respect to patients without ketoacidosis at onset. Moreover, the levels of TRAIL at diagnosis correlated inversely with the insulin requirement up to 21 months of follow-up. This is the first study demonstrating that the levels of circulating TRAIL are significantly decreased in T1D, with the lowest levels of TRAIL being observed in patients with ketoacidosis at the onset and with the highest insulin requirement.",
keywords = "Insulin requirement, Ketoacidosis, TRAIL, Type 1 diabetes mellitus",
author = "Gianluca Tornese and Dario Iafusco and Lorenzo Monasta and Chiara Agnoletto and Veronica Tisato and Alessandro Ventura and Giorgio Zauli and Paola Secchiero",
year = "2014",
doi = "10.1007/s00592-013-0507-5",
language = "English",
volume = "51",
pages = "239--246",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement

AU - Tornese, Gianluca

AU - Iafusco, Dario

AU - Monasta, Lorenzo

AU - Agnoletto, Chiara

AU - Tisato, Veronica

AU - Ventura, Alessandro

AU - Zauli, Giorgio

AU - Secchiero, Paola

PY - 2014

Y1 - 2014

N2 - Experimental evidence in animal models suggests that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, might play an important role in type 1 diabetes (T1D). We have performed a retrospective study by analyzing the sera of a cohort of pediatric subjects (age 18 years; n = 507) consisting of (1) patients diagnosed with T1D (n = 387), (2) healthy individuals (n = 98, considered as controls), and (3) healthy autoantibody-positive subjects (n = 22). Patients with T1D exhibited significantly decreased levels of circulating TRAIL with respect to the control healthy subjects, as well as to the healthy autoantibody-positive subjects. Within the T1D group, no differences in the levels of circulating TRAIL were observed between patients with or without other concomitant autoimmune pathologies. Of note, the levels of TRAIL were significantly lower in the T1D patients analyzed at onset, although reduction in TRAIL levels persisted also in patients analyzed after disease onset (>1 year from diagnosis). In particular, T1D patients who exhibited ketoacidosis at onset showed significantly lower levels of circulating TRAIL with respect to patients without ketoacidosis at onset. Moreover, the levels of TRAIL at diagnosis correlated inversely with the insulin requirement up to 21 months of follow-up. This is the first study demonstrating that the levels of circulating TRAIL are significantly decreased in T1D, with the lowest levels of TRAIL being observed in patients with ketoacidosis at the onset and with the highest insulin requirement.

AB - Experimental evidence in animal models suggests that TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, might play an important role in type 1 diabetes (T1D). We have performed a retrospective study by analyzing the sera of a cohort of pediatric subjects (age 18 years; n = 507) consisting of (1) patients diagnosed with T1D (n = 387), (2) healthy individuals (n = 98, considered as controls), and (3) healthy autoantibody-positive subjects (n = 22). Patients with T1D exhibited significantly decreased levels of circulating TRAIL with respect to the control healthy subjects, as well as to the healthy autoantibody-positive subjects. Within the T1D group, no differences in the levels of circulating TRAIL were observed between patients with or without other concomitant autoimmune pathologies. Of note, the levels of TRAIL were significantly lower in the T1D patients analyzed at onset, although reduction in TRAIL levels persisted also in patients analyzed after disease onset (>1 year from diagnosis). In particular, T1D patients who exhibited ketoacidosis at onset showed significantly lower levels of circulating TRAIL with respect to patients without ketoacidosis at onset. Moreover, the levels of TRAIL at diagnosis correlated inversely with the insulin requirement up to 21 months of follow-up. This is the first study demonstrating that the levels of circulating TRAIL are significantly decreased in T1D, with the lowest levels of TRAIL being observed in patients with ketoacidosis at the onset and with the highest insulin requirement.

KW - Insulin requirement

KW - Ketoacidosis

KW - TRAIL

KW - Type 1 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84898458607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898458607&partnerID=8YFLogxK

U2 - 10.1007/s00592-013-0507-5

DO - 10.1007/s00592-013-0507-5

M3 - Article

C2 - 23925693

AN - SCOPUS:84898458607

VL - 51

SP - 239

EP - 246

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 2

ER -